Clinical Trials Browser

Colonic Neoplasms, Gastrointestinal Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms

Neoplasm Metastasis

Carcinoma, Neoplasm Metastasis, Triple Negative Breast Neoplasms

Kidney Neoplasms, Melanoma, Neoplasm Metastasis

Melanoma, Neoplasm Metastasis, Skin Neoplasms

Melanoma, Neoplasm Metastasis

Carcinoma, Renal Cell, Melanoma, Neoplasm Metastasis

Uterine Cervical Neoplasms, Lung Neoplasms, Mesothelioma, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms

Urinary Bladder Neoplasms, Breast Neoplasms, Uterine Cervical Neoplasms, Kidney Neoplasms, Melanoma, Neoplasm Metastasis

Kidney Neoplasms

Uveal Melanoma, Neoplasm Metastasis

Neoplasms, Ovarian Neoplasms

Melanoma, Skin Neoplasms

Kidney Neoplasms

Melanoma, Neoplasms, Skin Neoplasms

Melanoma, Neoplasm Metastasis

Melanoma, Skin Neoplasms

Melanoma, Skin Neoplasms

Carcinoma, Renal Cell, Kidney Neoplasms, Melanoma

Neoplasm Metastasis, Neoplasms

Kidney Neoplasms, Melanoma

Carcinoma, Renal Cell, Kidney Neoplasms, Melanoma, Neoplasm Metastasis

Melanoma, Skin Neoplasms

Neuroblastoma

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

Melanoma, Skin Neoplasms

Melanoma, Melanoma, Experimental, Neoplasms

Clinical Trials

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients

Gene Therapy Using Anti-CEA Cells to Treat Metastatic Cancer

T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers

CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer

Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma

Vemurafenib and White Blood Cell Therapy for Advanced Melanoma

Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer

CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive

Phase 1/2 Study of Metastatic Renal Cancer Using T-Cells Transduced With a T-Cell Receptor Which Recognizes TRAIL Bound to the DR4 Receptor

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma

p53 Vaccine for Ovarian Cancer

Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma

Vaccine Treatment of Kidney Cancer

Drosophila-generated CTL

T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma

Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma

Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma

Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer

Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients

Gene Therapy Using Anti-Her-2 Cells to Treat Metastatic Cancer

Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer

MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes

Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells

Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma

Interleukin-12 and Interleukin-2 in Treating Patients With Refractory or Recurrent Neuroblastoma

Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis Fungoides

Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Anti-gp100:154-162 TCR Gene Engineered Lymphocytes

Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma

Cyclophosphamide and Fludarabine Followed By an Autologous Lymphocyte Infusion and Interleukin-2 in Treating Patients With Refractory or Recurrent Metastatic Melanoma